IXHL
NASDAQIncannex Healthcare Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.06+0.04 (+1.49%)
01:45 PM07:45 PM
News · 26 weeks36+67%
2025-12-072026-05-31
Mix2190d
- SEC Filings11(52%)
- Other9(43%)
- Offering1(5%)
Latest news
25 items- SECSEC Form 10-Q filed by Incannex Healthcare Inc.10-Q - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep ApneaMELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA). The commencement of DReAMzz represents a major operational and strategic milestone for the Company as it advances IHL-42X toward late-stage clinical development and potential registration pathways. The Company has now completed extensive site feasibility assessments, identified all 14 clinical trial sites, completed manufacturing
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug DevelopmentMELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced it has been named the winner of the "Best New Technology Solution for Drug Development" award in the 10th annual MedTech Breakthrough Awards program. The award recognizes Incannex's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for the treatment of obstructive sleep apnea (OSA), and reinforces the Company's growing position at the forefront of next-generation therapeutic innovation. IHL-42X combines dronabinol and a
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech BreakthroughLOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market, today announced that Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex"), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, has been selected as winner of the "Best New Technology Solution for Drug Development" in the 10th annual MedTech Breakthrough Awards program. The award specifically recognizes the Company's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental IllnessMELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, "Accelerating Medical Treatments for Serious Mental Illness." The Company believes its PSX-001 development program aligns with the goals outlined in the Executive Order and believes the data demonstrated to date, along with a more amenable regulatory environment, may provide significant hope for those suffering from anxiety disorders. "We agree with the Administration's recognition that
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic PositionMELBOURNE, Australia and NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The Company has utilized the buyback program opportunistically in the past, however had not actively repurchased shares in recent periods. The decision to reinitiate buyback activity reflects the Board of Directors' view that the Company's current market valuation does not accurately reflect the strength of its balance sheet, clinical prog
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea ResearchMELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation's Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026. The partnership reflects the Company's commitment to the broader sleep medicine community as it con
- SECSEC Form 8-K filed by Incannex Healthcare Inc.8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X DevelopmentMELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors. At current trading levels, Incannex's market capitalization is approximately $46 million — representing a significant disconnect to the Company's $75 million cash position and resulting in a negative enterprise value. Management believes this disconnect does not reflect the Company'
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Regains Compliance with Nasdaq Minimum Bid Price RequirementMELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026. As a result, the Company has satisfied t
- SECSEC Form 424B5 filed by Incannex Healthcare Inc.424B5 - Incannex Healthcare Inc. (0001873875) (Filer)
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IHXL), ("Incannex" or the "Company") a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying common warrants to purchase up to an aggregate of 2,000,000 shares of its common stock at a combined purchase price of $5.00 per share and accompanying common warrants. The financing is expected to generate agg
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- PRIncannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 OutcomesMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA), following statistically significant outcomes across key endpoints in its completed Phase 2 program. Importantly, IHL-42X has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), enabling more frequent interaction with the FDA as the program advances. The updated development strategy includes a Phase 2 crossover do
- PRIncannex Announces Reverse Stock SplitMELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 26, 2026. The Company's common stock will open for trading under a new CUSIP numb
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
- SECSEC Form 10-Q filed by Incannex Healthcare Inc.10-Q - Incannex Healthcare Inc. (0001873875) (Filer)
- SECIncannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Incannex Healthcare Inc. (0001873875) (Filer)
IXHL FAQ
5 questionsWhat does Incannex Healthcare Inc. do?
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as...Where does IXHL stock trade?
Incannex Healthcare Inc. (IXHL) is listed on NASDAQ.What sector and industry is IXHL in?
Incannex Healthcare Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IXHL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IXHL side-by-side with any of them on Quantisnow.How can I track IXHL on Quantisnow?
Quantisnow aggregates Incannex Healthcare Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IXHL to receive live email and push alerts on every new disclosure.